ES2799515T3 - ADN extracelular como una diana terapéutica en la neurodegeneración - Google Patents
ADN extracelular como una diana terapéutica en la neurodegeneración Download PDFInfo
- Publication number
- ES2799515T3 ES2799515T3 ES16800375T ES16800375T ES2799515T3 ES 2799515 T3 ES2799515 T3 ES 2799515T3 ES 16800375 T ES16800375 T ES 16800375T ES 16800375 T ES16800375 T ES 16800375T ES 2799515 T3 ES2799515 T3 ES 2799515T3
- Authority
- ES
- Spain
- Prior art keywords
- dnase
- pharmaceutical composition
- disease
- neurodegeneration
- extracellular dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 47
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 claims abstract description 88
- 108010053770 Deoxyribonucleases Proteins 0.000 claims abstract description 88
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 239000008280 blood Substances 0.000 claims abstract description 27
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 18
- 210000000936 intestine Anatomy 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 53
- 208000024827 Alzheimer disease Diseases 0.000 claims description 33
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 29
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 17
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 208000023105 Huntington disease Diseases 0.000 claims description 11
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 102000002151 Microfilament Proteins Human genes 0.000 claims description 4
- 108010040897 Microfilament Proteins Proteins 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 62
- 239000000203 mixture Substances 0.000 description 15
- 230000008499 blood brain barrier function Effects 0.000 description 14
- 210000001218 blood-brain barrier Anatomy 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 13
- 208000001089 Multiple system atrophy Diseases 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 230000000750 progressive effect Effects 0.000 description 10
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 9
- 229960004640 memantine Drugs 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 230000008092 positive effect Effects 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 206010003694 Atrophy Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010039966 Senile dementia Diseases 0.000 description 7
- 230000037444 atrophy Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000016273 neuron death Effects 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 206010044565 Tremor Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 108010067396 dornase alfa Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 208000004547 Hallucinations Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000010118 dystonia Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000010901 lateral sclerosis Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000005264 motor neuron disease Diseases 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 208000014094 Dystonic disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 108010056102 CD100 antigen Proteins 0.000 description 2
- 101001107784 Caenorhabditis elegans Deoxyribonuclease-2 Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100031149 Deoxyribonuclease gamma Human genes 0.000 description 2
- 102100022872 Deoxyribonuclease-1-like 1 Human genes 0.000 description 2
- 101710094552 Deoxyribonuclease-1-like 1 Proteins 0.000 description 2
- 102100031155 Deoxyribonuclease-1-like 2 Human genes 0.000 description 2
- 206010013142 Disinhibition Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 206010019070 Hallucination, auditory Diseases 0.000 description 2
- 206010019075 Hallucination, visual Diseases 0.000 description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 101000845621 Homo sapiens Deoxyribonuclease-1-like 2 Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 108010031616 deoxyribonuclease gamma Proteins 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003990 molecular pathway Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000003755 striatonigral degeneration Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- FVBVEHVQVWFUKG-UMSGYPCISA-N 4-[[dithiocarboxy-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]amino]methyl]benzoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CN(C(S)=S)CC1=CC=C(C(O)=O)C=C1 FVBVEHVQVWFUKG-UMSGYPCISA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000007774 Broca Aphasia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008754 Choreoathetosis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010016212 Familial tremor Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108700038051 Melanotransferrin Proteins 0.000 description 1
- 102000051089 Melanotransferrin Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 101100091878 Plasmodium falciparum (isolate 3D7) rpoC2 gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 1
- 101710096361 Prostaglandin E synthase Proteins 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 102000003890 RNA-binding protein FUS Human genes 0.000 description 1
- 108090000292 RNA-binding protein FUS Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 1
- 206010048669 Terminal state Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 208000010771 expressive aphasia Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 101150029016 rpo3 gene Proteins 0.000 description 1
- 101150102864 rpoD gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/02—Thioester hydrolases (3.1.2)
- C12Y301/02021—Dodecanoyl-[acyl-carrier-protein] hydrolase (3.1.2.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165255P | 2015-05-22 | 2015-05-22 | |
| PCT/RU2016/000284 WO2016190780A1 (en) | 2015-05-22 | 2016-05-11 | Extracellular dna as a therapeutic target in neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2799515T3 true ES2799515T3 (es) | 2020-12-18 |
Family
ID=57393467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16800375T Active ES2799515T3 (es) | 2015-05-22 | 2016-05-11 | ADN extracelular como una diana terapéutica en la neurodegeneración |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11701410B2 (enExample) |
| EP (1) | EP3297657B1 (enExample) |
| JP (1) | JP6745873B2 (enExample) |
| CN (1) | CN108289932A (enExample) |
| ES (1) | ES2799515T3 (enExample) |
| RU (1) | RU2726131C2 (enExample) |
| WO (1) | WO2016190780A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2726131C2 (ru) | 2015-05-22 | 2020-07-09 | Дмитрий Дмитриевич Генкин | Внеклеточная днк в качестве терапевтической мишени при нейродегенерации |
| US20190083636A1 (en) * | 2017-04-25 | 2019-03-21 | Lipoxen Technologies Limited | Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i |
| WO2018217351A1 (en) | 2017-05-24 | 2018-11-29 | Tets Viktor Veniaminovich | Methods for treating and preventing diseases |
| ES2913665T3 (es) | 2017-09-18 | 2022-06-03 | Santersus Ag | Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación |
| EP3740581A4 (en) | 2018-01-16 | 2021-10-27 | CLS Therapeutics Limited | TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY |
| EP3787638A4 (en) | 2018-04-30 | 2023-10-18 | Tets, Viktor, Veniaminovich | TETZ PROTEINS AND PRION-LIKE PROTEINS AND RELATED METHODS |
| US11918610B2 (en) | 2018-06-29 | 2024-03-05 | Viktor Veniaminovich Tets | Methods for diagnosis and treatment of type 1 diabetes |
| US12480150B2 (en) | 2018-06-29 | 2025-11-25 | Viktor Veniaminovich Tets and Georgy Viktorovich TETS | Compositions for modulating gut microbiota |
| EP3818173A4 (en) | 2018-07-03 | 2022-04-06 | Tets, Viktor, Veniaminovich | METHODS FOR ASSESSING AND INHIBITING AGING AND DEVICES FOR DETERMINING BIOLOGICAL AGE |
| CN110129245B (zh) * | 2019-07-08 | 2020-12-04 | 南京工业大学 | 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用 |
| WO2021011368A1 (en) * | 2019-07-12 | 2021-01-21 | Dmitry Dmitrievich Genkin | Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity |
| EP4119149A1 (en) * | 2021-07-15 | 2023-01-18 | Foundation For Research And Technology Hellas | Extracellular vesicles comprising a therapeutic cargo |
| WO2023126672A1 (en) | 2021-12-27 | 2023-07-06 | Santersus Ag | Method and device for removal of circulating cell free dna |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224942A (en) | 1962-01-15 | 1965-12-21 | Rorer Inc William H | Anti-inflammatory, anti-edema and anti-thrombi drug |
| US3324002A (en) | 1962-09-17 | 1967-06-06 | Armour Pharma | Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids |
| JPS5826822A (ja) | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | 慢性腎炎治療剤 |
| JPS61293927A (ja) | 1986-06-18 | 1986-12-24 | Kaken Pharmaceut Co Ltd | 肝臓疾患予防治療剤 |
| US4985243A (en) | 1988-01-20 | 1991-01-15 | Ml Technology Ventures, L.P. | Composition and method for protecting against diseases caused by microorganisms |
| JP3162372B2 (ja) | 1988-12-23 | 2001-04-25 | ジェネンテク，インコーポレイテッド | ヒトｄｎアーゼ |
| US5464817A (en) | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| DE4024530A1 (de) | 1990-08-02 | 1992-02-06 | Klinger & Co Dr | Verfahren zur bekaempfung von viren |
| FR2666096B1 (fr) | 1990-08-21 | 1993-12-31 | Sfri Sa | Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu. |
| EP0599850B1 (en) | 1991-08-16 | 1996-01-10 | Vical, Inc. | Composition and method for treating cystic fibrosis |
| US5484589A (en) | 1992-04-20 | 1996-01-16 | Rufeld, Inc. | Anti-viral methods using RNAse and DNAse |
| NZ299257A (en) | 1992-06-08 | 2000-08-25 | Genentech Inc | Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase |
| WO1995000170A1 (en) | 1993-06-24 | 1995-01-05 | Rufeld, Inc. | Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i |
| CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| RU2099080C1 (ru) | 1994-02-11 | 1997-12-20 | Дмитрий Иванович Финько | Способ предотвращения развития рака |
| JP2986215B2 (ja) | 1994-03-04 | 1999-12-06 | ジェネンテック インコーポレイテッド | Ｄｎアーゼ含有医薬製剤 |
| US5830744A (en) | 1995-06-06 | 1998-11-03 | Human Genome Sciences, Inc. | Gene encoding human Dnase |
| US5889153A (en) | 1994-05-20 | 1999-03-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, method for producing the same and intermediate compound therefor |
| DE69736276T2 (de) | 1996-02-05 | 2007-08-30 | Genentech Inc., San Francisco | Menschliche dnase resistent gegen actininhibitoren |
| EP0929694A4 (en) | 1996-03-15 | 2002-05-02 | Penn State Res Found | DETECTION OF TUMOR-RELATED EXTRACELLULAR NUCLEIC ACID USING PLASMA OR BLOOD SERUM USING NUCLEIC ACID AMPLIFICATION TESTS |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US5855920A (en) | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| US6242426B1 (en) | 1997-07-25 | 2001-06-05 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
| US6455250B1 (en) | 1997-12-11 | 2002-09-24 | The Regents Of The University Of California | Endonuclease compositions and methods of use |
| EP1109552A4 (en) | 1998-07-16 | 2007-11-07 | Res Dev Foundation | NOVEL ANTICANCING AGENTS GENERATING DNA CLEAVAGE |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| JP2002530436A (ja) | 1998-11-25 | 2002-09-17 | ジェネティカ インコーポレイテッド | 増殖能を増強しかつ複製老化を防止する方法及び試薬 |
| JP2000229881A (ja) | 1999-02-10 | 2000-08-22 | Morinaga Milk Ind Co Ltd | 癌疾患の予後改善剤 |
| DE60035851D1 (de) | 1999-08-17 | 2007-09-20 | Tanuma | Deoxyribonuklease, dafür kodierendes gen und verfahren |
| US6428785B1 (en) | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
| UA78486C2 (uk) | 1999-12-10 | 2007-04-10 | Хемджен Корпорейшн | Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти) |
| WO2001074905A1 (en) | 2000-04-03 | 2001-10-11 | Antisoma Research Limited | Compounds for targeting |
| US6462017B1 (en) | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
| RU2202109C1 (ru) | 2001-08-03 | 2003-04-10 | Научно-исследовательский институт неврологии РАН | Способ выявления степени нарушения реологических свойств крови |
| RU2207876C1 (ru) | 2001-11-08 | 2003-07-10 | Ткаченко Виталий Васильевич | Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия |
| US7402724B2 (en) | 2002-01-04 | 2008-07-22 | Mayo Foundation For Medical Education And Research | Longevity and PAPP-A |
| WO2003068254A1 (en) * | 2002-02-18 | 2003-08-21 | University Of Southampton | Glycosaminoglycan-dnase combination therapy |
| DE10221194B4 (de) | 2002-05-13 | 2005-02-10 | Fryda, Waltraud, Dr.med. | Hyaluronidasehaltiges Hautpflegemittel |
| US20040001817A1 (en) | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| ATE360817T1 (de) | 2002-12-18 | 2007-05-15 | Coy Johannes F Dr | Verbindungen und verfahren zur nachweiss von karzinomen und deren vorstufen |
| RU2239442C1 (ru) | 2003-05-05 | 2004-11-10 | Красноярская государственная медицинская академия | Способ профилактики внутриутробных инфекций у детей |
| EP1666055A4 (en) | 2003-07-14 | 2010-02-10 | Viktor Veniaminovich Tets | METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| RU2269359C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты) |
| RU2269358C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| WO2005004904A1 (en) | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants) |
| US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
| RU2239404C1 (ru) | 2003-09-17 | 2004-11-10 | Бессонов Дмитрий Михайлович | Способ профилактики старения организма человека |
| RU2269357C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека |
| RU2267329C2 (ru) | 2004-03-12 | 2006-01-10 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты) |
| EP1734991A4 (en) | 2004-04-14 | 2012-10-24 | Avirid Inc | COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES |
| CN101171034B (zh) * | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| JP3989936B2 (ja) | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規ｄｎアーゼ |
| KR20080038131A (ko) | 2005-07-18 | 2008-05-02 | 프로탈릭스 리미티드 | 생물학적으로 활성인 거대분자의 점막 또는 장관 투여 |
| RU2308968C2 (ru) | 2005-07-19 | 2007-10-27 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации |
| US20080131497A1 (en) * | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
| DK2086642T3 (da) | 2006-10-18 | 2014-09-29 | Periness Ltd | Dnase til behandling af subfertilitet hos mænd |
| EP2095825B8 (en) * | 2006-11-28 | 2012-03-28 | CLS Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| GB0922006D0 (en) | 2009-12-17 | 2010-02-03 | Genome Res Ltd | Diagnostic |
| CA2814962A1 (en) * | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| US20130243794A1 (en) | 2010-12-03 | 2013-09-19 | Beth Israel Deaconess Medical Center, Inc. | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses |
| WO2013114371A1 (en) | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dry powder formulations of dnase i |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| KR102082735B1 (ko) | 2012-08-03 | 2020-02-28 | 훼링 비.브이. | 암컷 불임에 대한 치료학적 타겟 및 진단 마커로서의 세포-유리 dna |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| WO2015139093A1 (en) | 2014-03-21 | 2015-09-24 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | Stable gene transfer to proliferating cells |
| AU2015349759B2 (en) | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| RU2726131C2 (ru) | 2015-05-22 | 2020-07-09 | Дмитрий Дмитриевич Генкин | Внеклеточная днк в качестве терапевтической мишени при нейродегенерации |
| SG10201912763QA (en) | 2015-11-05 | 2020-02-27 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
| AU2017223964A1 (en) | 2016-02-25 | 2018-09-06 | Agenovir Corporation | Viral and oncoviral nuclease treatment |
-
2016
- 2016-05-11 RU RU2017145051A patent/RU2726131C2/ru active
- 2016-05-11 WO PCT/RU2016/000284 patent/WO2016190780A1/en not_active Ceased
- 2016-05-11 ES ES16800375T patent/ES2799515T3/es active Active
- 2016-05-11 JP JP2018513264A patent/JP6745873B2/ja active Active
- 2016-05-11 EP EP16800375.4A patent/EP3297657B1/en active Active
- 2016-05-11 US US15/576,611 patent/US11701410B2/en active Active
- 2016-05-11 CN CN201680042916.0A patent/CN108289932A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018520208A (ja) | 2018-07-26 |
| WO2016190780A1 (en) | 2016-12-01 |
| JP6745873B2 (ja) | 2020-08-26 |
| RU2017145051A3 (enExample) | 2019-06-24 |
| EP3297657A1 (en) | 2018-03-28 |
| CN108289932A (zh) | 2018-07-17 |
| RU2726131C2 (ru) | 2020-07-09 |
| RU2017145051A (ru) | 2019-06-24 |
| EP3297657A4 (en) | 2018-11-14 |
| US11701410B2 (en) | 2023-07-18 |
| US20180360925A1 (en) | 2018-12-20 |
| EP3297657B1 (en) | 2020-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11701410B2 (en) | Extracellular DNA as a therapeutic target in neurodegeneration | |
| US20240390480A1 (en) | Nucleic acid vaccines | |
| US10682373B2 (en) | Method for treating a degenerative neurological disorders comprising administering ASM inhibitor | |
| Zhang et al. | Endoplasmic reticulum stress is involved in restraint stress-induced hippocampal apoptosis and cognitive impairments in rats | |
| Tsilioni et al. | Exosomes in neurologic and psychiatric disorders | |
| ES2930628T3 (es) | Uso de pridopidina para mejorar la memoria | |
| ES2606554T3 (es) | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 | |
| US20170042924A1 (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
| Zhao et al. | Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model | |
| JP2017518043A (ja) | Ｐ９７−ポリヌクレオチド複合体 | |
| WO2021108602A1 (en) | Methods and compositions for neuroprotection | |
| ES2743622T3 (es) | Tratamiento de la enfermedad autoinmune y/o inflamatoria usando moduladores de la caveolina novedosos | |
| US11242529B2 (en) | Method for treating a neurological disorder comprising administering ASM inhibitors | |
| EP3634460A1 (en) | S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy | |
| KR101401744B1 (ko) | Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 | |
| Ketata et al. | From pathological mechanisms in Krabbe disease to cutting‐edge therapy: A comprehensive review | |
| ES2369760T3 (es) | Péptido bloqueante para la secreción de células inflamatorias. | |
| KR20210151062A (ko) | 히알루로난 접합체 및 이의 용도 | |
| US20170209402A1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| KR20240004531A (ko) | 신경 장애의 치료 및/또는 예방을 위한 알파-1-항트립신(aat) | |
| WO2020024071A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| WO2004080476A1 (en) | Use of secretin in the treatment of schizophrenia | |
| ES2337255T3 (es) | Uso de pirazolopiridinas para el tratamiento de deficit cognitivos. | |
| US20240398792A1 (en) | Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease | |
| EP3723777A1 (en) | Compositions comprising bacterial strains |